Matches in SemOpenAlex for { <https://semopenalex.org/work/W2501649281> ?p ?o ?g. }
- W2501649281 endingPage "55703" @default.
- W2501649281 startingPage "55690" @default.
- W2501649281 abstract "// Ayman A.M. Alameen 1, 2, * , Carolina Simioni 1, * , Alberto M. Martelli 3 , Giorgio Zauli 1 , Simona Ultimo 1 , James A. McCubrey 4 , Arianna Gonelli 1 , Giorgia Marisi 5 , Paola Ulivi 5 , Silvano Capitani 1, 6 , Luca M. Neri 1 1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy 2 Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan 3 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy 4 Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA 5 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy 6 LTTA Center, University of Ferrara, Ferrara, Italy * These authors have contributed equally to this work Correspondence to: Luca M. Neri, email: luca.neri@unife.it Silvano Capitani, email: silvano.capitani@unife.it Keywords: T lymphocytes, PI3K/Akt/mTOR signaling, T-acute lymphoblastic leukemia, targeted therapies, autophagy Received: May 05, 2016 Accepted: July 11, 2016 Published: August 1, 2016 ABSTRACT An attractive molecular target for novel anti-cancer therapies is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway which is commonly deregulated in many types of cancer. Nevertheless, the effects of PI3K/Akt/mTOR inhibitors on T lymphocytes, a key component of immune responses, have been seldom explored. In this study we investigated the effects on human CD4 + T-cells of a panel of PI3K/Akt/mTOR inhibitors: BGT226, Torin-2, MK-2206, and ZSTK474. We also assessed their efficacy against two acute leukemia T cell lines. T lymphocytes were stimulated with phytohemagglutinin. Inhibitor effects on cell cycle and apoptosis were analyzed by flow cytometry, while cytotoxicity was assessed by MTT assays. In addition, the activation status of the pathway as well as induction of autophagy were analyzed by Western blotting. Quiescent healthy T lymphocytes were unaffected by the drugs whereas mitogen-stimulated lymphocytes as well as leukemic cell lines displayed a cell cycle block, caspase-dependent apoptosis, and dephosphorylation of key components of the signaling pathway. Autophagy was also induced in proliferating lymphocytes and in JURKAT and MOLT-4 cell lines. When autophagy was inhibited by 3-methyladenine or Bafilomycin A1, drug cytotoxicity was increased, indicating that autophagy is a protective mechanism. Therefore, our findings suggest that PI3K/Akt/mTOR inhibitors preserve lymphocyte viability. This is a valuable result to be taken into account when selecting drugs for targeted cancer therapy in order to minimize detrimental effects on immune function." @default.
- W2501649281 created "2016-08-23" @default.
- W2501649281 creator A5028358932 @default.
- W2501649281 creator A5030391285 @default.
- W2501649281 creator A5036936997 @default.
- W2501649281 creator A5036994059 @default.
- W2501649281 creator A5037164805 @default.
- W2501649281 creator A5041478223 @default.
- W2501649281 creator A5042887836 @default.
- W2501649281 creator A5058164461 @default.
- W2501649281 creator A5066321949 @default.
- W2501649281 creator A5074326702 @default.
- W2501649281 creator A5082203114 @default.
- W2501649281 date "2016-08-01" @default.
- W2501649281 modified "2023-09-25" @default.
- W2501649281 title "Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia" @default.
- W2501649281 cites W1058891070 @default.
- W2501649281 cites W1493876987 @default.
- W2501649281 cites W1503514494 @default.
- W2501649281 cites W1526339950 @default.
- W2501649281 cites W1548830643 @default.
- W2501649281 cites W1607603286 @default.
- W2501649281 cites W1752845679 @default.
- W2501649281 cites W1940068179 @default.
- W2501649281 cites W1981606991 @default.
- W2501649281 cites W1986585212 @default.
- W2501649281 cites W1991692801 @default.
- W2501649281 cites W2006613419 @default.
- W2501649281 cites W2012306540 @default.
- W2501649281 cites W2023804723 @default.
- W2501649281 cites W2023890731 @default.
- W2501649281 cites W2025786205 @default.
- W2501649281 cites W2035216470 @default.
- W2501649281 cites W2043260184 @default.
- W2501649281 cites W2045178199 @default.
- W2501649281 cites W2052273633 @default.
- W2501649281 cites W2052874737 @default.
- W2501649281 cites W2067416677 @default.
- W2501649281 cites W2068515861 @default.
- W2501649281 cites W2068789756 @default.
- W2501649281 cites W2070361307 @default.
- W2501649281 cites W2074342156 @default.
- W2501649281 cites W2078521685 @default.
- W2501649281 cites W2081758915 @default.
- W2501649281 cites W2087037634 @default.
- W2501649281 cites W2099208844 @default.
- W2501649281 cites W2109316293 @default.
- W2501649281 cites W2111018421 @default.
- W2501649281 cites W2117692326 @default.
- W2501649281 cites W2118754985 @default.
- W2501649281 cites W2120943945 @default.
- W2501649281 cites W2125083914 @default.
- W2501649281 cites W2126569401 @default.
- W2501649281 cites W2127011486 @default.
- W2501649281 cites W2127532659 @default.
- W2501649281 cites W2130122821 @default.
- W2501649281 cites W2130622321 @default.
- W2501649281 cites W2140154966 @default.
- W2501649281 cites W2143596987 @default.
- W2501649281 cites W2143945587 @default.
- W2501649281 cites W2144562196 @default.
- W2501649281 cites W2144687234 @default.
- W2501649281 cites W2146414563 @default.
- W2501649281 cites W2148181678 @default.
- W2501649281 cites W2148976095 @default.
- W2501649281 cites W2157782360 @default.
- W2501649281 cites W2159750196 @default.
- W2501649281 cites W2168023789 @default.
- W2501649281 cites W2285555086 @default.
- W2501649281 cites W2292075477 @default.
- W2501649281 cites W2295277526 @default.
- W2501649281 cites W2310474004 @default.
- W2501649281 cites W2310576747 @default.
- W2501649281 cites W2314701251 @default.
- W2501649281 cites W2315622814 @default.
- W2501649281 cites W2325271619 @default.
- W2501649281 cites W2331089484 @default.
- W2501649281 cites W2338801484 @default.
- W2501649281 cites W2410167871 @default.
- W2501649281 cites W4233175927 @default.
- W2501649281 cites W4238567307 @default.
- W2501649281 cites W4251622665 @default.
- W2501649281 doi "https://doi.org/10.18632/oncotarget.10984" @default.
- W2501649281 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5342446" @default.
- W2501649281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27494886" @default.
- W2501649281 hasPublicationYear "2016" @default.
- W2501649281 type Work @default.
- W2501649281 sameAs 2501649281 @default.
- W2501649281 citedByCount "14" @default.
- W2501649281 countsByYear W25016492812017 @default.
- W2501649281 countsByYear W25016492812018 @default.
- W2501649281 countsByYear W25016492812019 @default.
- W2501649281 countsByYear W25016492812020 @default.
- W2501649281 countsByYear W25016492812021 @default.
- W2501649281 countsByYear W25016492812023 @default.
- W2501649281 crossrefType "journal-article" @default.
- W2501649281 hasAuthorship W2501649281A5028358932 @default.
- W2501649281 hasAuthorship W2501649281A5030391285 @default.